{
    "root": "8d633546-b681-47fd-a701-1bfe173dff67",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20240729",
    "ingredients": [
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        },
        {
            "name": "ALUMINUM HYDROXIDE",
            "code": "5QB0T2IUN0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16234"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "Polyvinyl Acetate Phthalate",
            "code": "58QVG85GW3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30089"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM ALGINATE",
            "code": "C269C4G2ZQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53311"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . diclofenac sodium delayed-release tablets indicated : relief signs symptoms osteoarthritis relief signs symptoms rheumatoid arthritis acute long-term relief signs symptoms ankylosing spondylitis",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ; gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac sodium delayed-release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100 mg/day 150 mg/day divided doses ( 50 mg twice day three times day , 75 mg twice day ) . relief rheumatoid arthritis , recommended 150 mg/day 200 mg/day divided doses ( 50 mg three times day . four times day , 75 mg twice day ) . relief ankylosing spondylitis , recommended 100 mg/day 125 mg/day , administered 25 mg four times day , extra 25-mg dose bedtime necessary . different formulations diclofenac ( diclofenac sodium delayed-release tablets , usp ; diclofenac sodium extended-release tablets , usp ; diclofenac potassium immediate-release tablets ) necessarily bioequivalent even milligram strength .",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "diclofenac sodium delayed-release tablets , usp available follows : 50 mg \u2014 white , round , enteric-coated tablet printed one side 550 side black ink contains 50 mg diclofenac sodium , usp . tablets supplied bottles 60 ( ndc 0228-2550-06 ) , 100 ( ndc 0228-2550-11 ) 1000 ( ndc 0228-2550-96 ) . 75 mg \u2014 white , round , enteric-coated tablet printed one side 551 side black ink contains 75 mg diclofenac sodium , usp . tablets supplied bottles 60 ( ndc 0228-2551-06 ) , 100 ( ndc 0228-2551-11 ) , 1000 ( ndc 0228-2551-96 ) . store 25\u00bac ( 77\u00baf ) ; excursions permitted 15\u00ba 30\u00bac ( 59\u00ba 86\u00baf ) . protect moisture . dispense tight , light-resistant container defined usp . dispense medication guide available : www.tevausa.com/medguides manufactured : teva pharmaceuticals parsippany , nj 07054 rev . 7/2024",
    "adverseReactions": "diclofenac sodium delayed-release tablets contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( ; anaphylactic , serious skin ) . history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( ; anaphylactic , exacerbation asthma related aspirin sensitivity ) . setting coronary artery bypass graft ( cabg ) surgery ( ; cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis\n                     for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 mg/day to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 mg/day to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 mg/day to 125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium delayed-release tablets, USP; diclofenac sodium extended-release tablets, USP; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac sodium delayed-release tablets, USP are available as follows:\n                  50 mg \u2014 Each white, round, enteric-coated tablet printed with \u00a0on one side and 550 on the other side with black ink contains 50 mg of diclofenac sodium, USP. Tablets are supplied in bottles of 60 (NDC 0228-2550-06), 100 (NDC 0228-2550-11) and 1000 (NDC 0228-2550-96).\n                  75 mg \u2014 Each white, round, enteric-coated tablet printed with \u00a0on one side and 551 on the other side with black ink contains 75 mg of diclofenac sodium, USP. Tablets are supplied in bottles of 60 (NDC 0228-2551-06), 100 (NDC 0228-2551-11), and 1000 (NDC 0228-2551-96).\n                  Store at 25\u00baC (77\u00baF); excursions permitted to 15\u00ba to 30\u00baC (59\u00ba to 86\u00baF). Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  Dispense with Medication Guide available at: www.tevausa.com/medguides\n                  Manufactured For:\n                     Teva Pharmaceuticals\n                     Parsippany, NJ 07054\n                  Rev. D 7/2024",
    "adverseReactions_original": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS; Anaphylactic Reactions, Serious Skin Reactions).\n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS; Anaphylactic Reactions, Exacerbation of Asthma Related to Aspirin Sensitivity).\n                     In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS; Cardiovascular Thrombotic Events).",
    "drug": [
        {
            "name": "Diclofenac Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ]
}